Bacterial etiology of bloodstream infections and antimicrobial resistance in Dhaka, Bangladesh, 2005–2014 by Dilruba Ahmed et al.
RESEARCH Open Access
Bacterial etiology of bloodstream infections
and antimicrobial resistance in Dhaka,
Bangladesh, 2005–2014
Dilruba Ahmed*, Md Ausrafuggaman Nahid, Abdullah Bashar Sami, Farhana Halim, Nasrin Akter, Tuhin Sadique,
Md Sohel Rana, Md Shahriar Bin Elahi and Md Mahbubur Rahman
Abstract
Background: Bloodstream infections due to bacterial pathogens are a major cause of morbidity and mortality in
Bangladesh and other developing countries. In these countries, most patients are treated empirically based on their
clinical symptoms. Therefore, up to date etiological data for major pathogens causing bloodstream infections may
play a positive role in better healthcare management. The aim of this study was to identify the bacterial pathogens
causing major bloodstream infections in Dhaka, Bangladesh and determine their antibiotic susceptibility pattern.
Methods: From January 2005 to December 2014, a total of 103,679 single bottle blood samples were collected
from both hospitalized and domiciliary patients attending Dhaka hospital, icddrb, Bangladesh All the blood samples
were processed for culture using a BACT/Alert blood culture machine. Further identification of bacterial pathogens
and their antimicrobial susceptibility test were performed using standard microbiological procedures.
Results: Overall, 13.6% of the cultured blood samples were positive and Gram-negative (72.1%) bacteria were
predominant throughout the study period. Salmonella Typhi was the most frequently isolated organism (36.9%
of samples) in this study and a high percentage of those strains were multidrug-resistant (MDR). However, a
decreasing trend in the S. Typhi isolation rate was observed and, noticeably, the percentage of MDR S. Typhi
isolated declined sharply over the study period. An overall increase in the presence of Gram-positive bacteria was
observed, but most significantly we observed the percentage of MDR Gram-positive bacteria to double over the
study period. Overall, Gram positive bacteria were more resistant to most of the commonly used antibiotics than
Gram-negative bacteria, but the MDR level was high in both groups.
Conclusions: This study identified the major bacterial pathogens involved with BSI in Dhaka, Bangladesh and also
revealed their antibiotic susceptibility patterns. We expect our findings to help healthcare professionals to make
informed decisions and provide better care for their patients. Also, we hope this study will assist researchers and
policy makers to prioritize their research options to face the future challenges of infectious diseases.
Keywords: Bloodstream infection, BSI, Antimicrobial resistance, Multidrug-resistance (MDR), Epidemiology,
Gram-positive bacteria, Gram-negative bacteria, Dhaka, Bangladesh
* Correspondence: dahmed@icddrb.org
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
Dhaka 1212, Bangladesh
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ahmed et al. Antimicrobial Resistance and Infection Control  (2017) 6:2 
DOI 10.1186/s13756-016-0162-z
Background
Bloodstream infection (BSI) due to bacterial pathogens
is a global concern. It is often associated with increased
length of hospital stay, a significant amount of health-
care related costs and most significantly, a high rate of
morbidity and mortality [1]. Depending on the age, se-
verity of infection and other risk factors, the mortality
rate for BSI varies between 4.0 and 41.5% [2–7]. Recent
studies have reported a rapid increase in the number of
bloodstream infections from both community and noso-
comial sources [8, 9]. Staphylococcus aureus, Streptococcus
pneumoniae and Escherichia coli have been found to be
the most commonly isolated pathogens associated with
BSI worldwide [3, 6].
The epidemiology of BSI varies depending on the geo-
graphic location, age and co-morbid illnesses. As an
example, Salmonella enterica is a frequently isolated
pathogen from blood samples in both African and Asian
regions, however their serotypes differ substantially [10]. S.
Paratyphi is the predominant organism in the Salmonella
group in Africa whereas S. Typhi is the most frequently
isolated organism in Asia. Besides their isolation rate, their
antibiotic susceptibility pattern varies substantially [10]. So,
understanding of local epidemiology may play an import-
ant role in making proper empirical treatment choices be-
fore laboratory test results are available. This is especially
true for Bangladesh and other developing countries where
healthcare systems operate on poor hygiene system and
lack proper facilities to contain infections. In these
countries, early treatment is usually based on the patient’s
clinical symptoms rather than diagnostic results. Therefore,
patient’s early prognosis to final outcome might be much
improved by available epidemiologic data for the most
frequently isolated pathogenic organisms. However,
complete data on BSI causing organisms from Dhaka,
Bangladesh is scarce.
In this study, we aimed to identify the most prevalent
bacterial pathogens involved in BSI in hospital and
domiciliary patients from Dhaka, Bangladesh. We also
determined pathogen antibiotic susceptibility patterns to
evaluate the changing trend of antimicrobial susceptibil-
ity in this region.
Methods
In this retrospective study, blood samples were obtained
from patients attending out-patient and in-patient ser-
vices at Dhaka hospital, icddrb, Bangladesh which is a
primary care hospital with 200 in-patient beds. A total
of 103679 blood samples were processed from January
2005 to December 2014. In the consecutive ten years of
the study 9600, 9364, 9189, 9523, 9523, 11578, 11179,
10822, 10161 and 12740 samples were received and
processed from 2005 to 2014 respectively. All the blood
samples were processed for culture using a BACT/Alert
blood culture machine to identify the presence of bacter-
ial pathogens. Antimicrobial susceptibility tests were
performed on the isolated pathogens using standard
microbiological procedures [11].
Bacterial isolation
Collected blood samples were directly inoculated into
adult (more than 12 years of age) and pediatric (up to
12 years of age) FAN blood culture bottle. Bottles were
incubated in the BACT/Alert machine for up to 5 days.
Positive culture samples were directly inoculated onto
MacConkey (MC) agar, chocolate agar and blood agar
(5% sheep blood) plates. MC plates were then incubated
at 35 °C in aerobic condition. Chocolate and blood agar
plates were incubated at 35 °C in microaerophilic condi-
tion (containing 5% CO2). Bacterial pathogens were
identified using standard bacteriological procedures [11].
API identification strips (bioMérieux, France) were used
as supportive tests for further identification.
Antimicrobial susceptibility testing
Antimicrobial susceptibility tests were performed by
using the disk diffusion method and susceptibility
patterns were determined following CLSI guidelines
[11–14]. The study was begun following CLSI, 2004
guidelines [14] and later the relevant changes made in
2010, 2012 and 2013 by CLSI were incorporated. Break-
point changes made in 2010 and 2013 for carbapenems
in the case of Enterobacteriaceae [12, 13] were adapted,
and also the revised ciprofloxacin breakpoint for
Salmonella in 2012 [11]. Antibiotic susceptibility was
tested for CN (10 μg), SXT (25 μg), Cip (5 μg), CRO
(30 μg), AMP (10 μg), Caz (30 μg), Imp (10 μg), Net
(30 μg), Ak (30 μg), CFM (5 μg), Azi (15 μg), Pen G
(10 μg), E (15 μg), C (30 μg), Van (30 μg) and Tet (30 μg).
All the antibiotic disks were obtained from Oxoid, UK. E.
coli ATCC 25922 and Pseudomonas aeruginosa ATCC
27853 were used as quality control strains.
We were not able to find any standard definition of
multidrug-resistance (MDR) and observed that many
previous studies have used the definition of MDR as re-
sistance against three or more classes of antibiotics both
for Gram-positive [15–17] and Gram-negative [18–21]
bacteria. Consequently, the definition of MDR as ac-
quired non-susceptibility against at least three classes of
antibiotics was adopted. Salmonella species were tested
against six classes of antibiotics; penicillin and cephalo-
sporin (AMP, CRO, CFM), aminoglycosides (CN), fluor/
quinolones (Cip, NA), sulfonamides (SXT), macrolides
(Azi) and chloramphenicol. Other Gram-negative bac-
teria were tested against seven classes of antibiotics;
penicillin and cephalosporin (AMP, CRO, CFM, Caz),
carbapenems (Imp, Mem), aminoglycosides (CN, Net,
Ak), fluoro/quinolones (Cip, NA), sulfonamides (SXT),
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macrolides (Azi) and chloramphenicol. Gram-positive
bacteria were tested against seven classes of antibiotics;
penicillin and cephalosporin (AMP, Pen G, Oxa, CRO,
CFM), carbapenems (Imp), aminoglycosides (CN), fluor/
quinolones (Cip), sulfonamides (SXT), macrolides (Azi, E)
and others (C, Van, Rif).
Statistical analysis
Blood-borne pathogen trends for isolation and anti-
microbial susceptibility over the last ten years was deter-
mined using χ2 (chi-square) test for trend in SPSS
version 16.0. P value ≤ 0.05 was considered significant.
Standard error of the mean (SEM) was calculated for
mean isolation rates. Odd ratios for age and sex were
calculated to show their association with infection by
particular organisms, and SPSS version 16.0 was used
for this purpose. For age, an odds ratio greater than 1.0
indicated the association of a pathogen with age group
of less than five years old, and an odds ratio of less than
1.0 indicated the association of a pathogen with age
group of more than five years old. For sex, an odds ratio
of less than 1.0 indicated the association of a pathogen
with female patient group and an odds ratio of more
than 1.0 indicated an association of that pathogen with
male patient group.
Results
From January 2005 to December 2014, a total of 103,679
blood samples were received from both hospitalized and
domiciliary patients and among them 14015 samples
were found to be culture positive. Over these past ten
years 11.9, 12.2, 13.9, 16.5, 16.0, 17.3, 12.7, 12.9, 10.7
and 11.9% of the samples were found to be culture posi-
tive (P < 0.001) respectively. The mean culture positive
rate was 13.6 ± 0.7%. Table 1 shows the distribution of
organisms found throughout this study period. Blood
samples were received from patients with age range of
1 day to 115 years and the mean age was 18 years. S.
Typhi was the most frequently isolated blood-borne bac-
terial pathogen in this study, accounting for 36.9% of the
total isolates. Other frequently isolated pathogens in-
cluded coagulase-negative Staphylococcus species (21.5%),
Pseudomonas species (12.5%), S. Paratyphi A, B (8.9%)
and Acinetobacter species (5.1%).
Pseudomonas species and Acinetobacter species were
the two major non-fermenter bacteria isolated between
2005 and 2014. Pseudomonas species showed a sharp
increase in isolation rate, from 40.6 to 79.2% (χ2 = 105.1,
P < 0.001) of the total non-fermenter bacteria, between
2005 and 2010. However, for the next four years their
isolation rate decreased slightly and reached 74.3% in
2014. Acinetobacter species showed a decreasing trend
in their isolation rate over this study period, from
49.8 to 24.4% (χ2 = 95.5, P < 0.001). Salmonella species
accounted for 46.7% of the total blood-borne pathogens.
We observed an overall decreasing trend in their isolation
rate from 2005 to 2014 (χ2 = 306.5, P < 0.001). Besides non-
fermenter and Salmonella species, other Gram-negative
bacteria constituted only 7.7% (χ2 = 72.0, P < 0.001) of the
total blood-borne pathogens. E. coli, Enterobacter species
and Serratia species had a steady isolation rate over the
ten year period, while Klebsiella species showed an in-
creasing trend in their isolation rate, from 22.6 to 50.9%
(χ2 = 29.1, P < 0.01) of the total Gram-negative bacterial
group (excluding Salmonella species). Gram-positive
bacteria accounted for 27.7% of the total blood-borne path-
ogens. Their isolation rate increased from 20.6 to 30.8%
(χ2 = 351.7, P < 0.001) over study period. From 2005 to
2014, Streptococcus pneumoniae showed a decreasing trend
in their isolation rate, from 20.8 to 5.6% (χ2 = 158.7,
P < 0.001) of the total Gram-positive bacteria.
We observed significant associations between different
age groups and infection from specific pathogenic or-
ganisms (Additional file 1: Table S7). Pseudomonas
species (OR: 0.383, 0.341- 0.430, P < 0.001), S. Paratyphi
A, B (0.510, 0.449-0.579, P < 0.001) and Serratia species
(0.592, 0.373-0.941, P < 0.05) had significant associations
with age group of more than five years old. On the other
hand, non-typhoidal Salmonella species (5.082, 3.171-
8.146, P < 0.001) and S. pneumoniae (3.827, 2.922-5.012,
P < 0.001) had significant association with age group of
less than five years old. We also observed the association
of sex with infection from different pathogenic bacteria
(Additional file 2: Table S8). S. aureus (1.348, 1.019-
1.783, P < 0.05) infection was significantly associated
with the male patient group, while E. coli (0.705, 0.581-
0.855, P < 0.001) was more associated with the female
patient group. Seasonal fluctuation was also observed in
the incidence rate of a few pathogens (Fig. 1). Acineto-
bacter species (April-May), Enterobacter species (July), S.
aureus (March and November) and S. pneumoniae
(March) showed distinct seasonal peaks.
Acinetobacter species showed an increasing trend of re-
sistance against gentamicin (χ2 = 101.6, P < 0.001), ceftri-
axone (χ2 = 51.8, P < 0.001) and ciprofloxacin (χ2 = 135.2,
P < 0.001) (Additional file 3: Table S1). Pseudomonas
species also showed an increasing trend of resistance
against gentamicin (χ2 = 127.5, P < 0.001), and ciprofloxa-
cin (χ2 = 141.7, P < 0.001) (Additional file 4: Table S2).
Additionally, Acinetobacter species and Pseudomonas spe-
cies showed an overall 56.2, 47.6, 32.8, 51.4 and 23.0, 17.4,
56.2, 50.8% resistance against ceftazidime, imipenem,
netilmicin and amikacin respectively. Table 2 shows the
distribution of their MDR strains over this study period.
S. Typhi was found to be consistently sensitive to cef-
triaxone and cefixime over this study period; however, a
strain of ESBL S. Typhi was reported [22]. At the same
time, decreasing trends of resistance against ampicillin
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(χ2 = 540.4, P < 0.001) and co-trimoxazole (χ2 = 740.3,
P < 0.001) were observed. S. Paratyphi A, B was found to
be consistently susceptible to ampicillin, co-trimoxazole,
ceftriaxone and cefixime over the ten year period. Notice-
ably, both S. Typhi and S. Paratyphi A, B showed a trend
of increasingly reduced susceptibility against ciprofloxacin
(χ2 = 24.3 and 66.1 respectively, P < 0.001) throughout this
study period (Table 3).
E. coli and Enterobacter species showed an increasing
trend of resistance against gentamicin (χ2 = 52.44 and
statistically insignificant respectively, P < 0.001) and
ceftriaxone (χ2 = 52.4 and 16.5 respectively, P < 0.001). A
reducing trend of susceptibility against ciprofloxacin
(χ2 = 89.9 and 86.8 respectively, P < 0.001) was also ob-
served (Table 4 and Additional file 5: Table S4). Addition-
ally, E. coli showed an overall increase in resistance, from
69.0 to 90.0%, against co-trimoxazole and ampicillin be-
tween 2005 and 2014. Klebsiella species showed an in-
creasing trend of resistance against imipenem (χ2 = 79.6,
P < 0.001), and a reducing trend of susceptibility
against ciprofloxacin (χ2 = 36.1, P < 0.001) (Additional
file 6: Table S3). Over the same time period an overall
increase in resistance, from 62.0 to 76.0%, was observed
against gentamicin and ceftriaxone respectively for
Klebsiella species. Additionally, Klebsiella species showed
an overall 86.0, 33.0 and 70.0% resistance against cefixime,
meropenem and azithromycin respectively from 2010
to 2014.
S. pneumoniae was found to be consistently suscep-
tible to ampicillin and ceftriaxone between 2005 and
2014 (Table 5). Over this period, their resistance to co-
trimoxazole reduced (χ2 = 92.5, P < 0.001). However, it
increased against penicillin G (χ2 = 195.3, P < 0.001) and
erythromycin (χ2 = 293.2, P < 0.001). Also, a trend of in-
creased susceptibility was observed against ciprofloxacin
(χ2 = 79.2, P < 0.001). Other Streptococcus species
showed an increasing trend of resistance against genta-
micin (χ2 = 44.9, P < 0.001) and erythromycin (χ2 = 70.0,
P < 0.001), while there was a reducing trend in sus-
ceptibility against ciprofloxacin (χ2 = 67.3, P < 0.001)
(Additional file 7: Table S5). S. aureus was found to be
highly resistant to ampicillin (up to 100%) throughout
Fig. 1 Seasonal variability of BSI causing pathogens- a Acinetobacter species, b Enterobacter species, c Staphylococcus aureus, d Streptococcus pneumoniae
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this study (Table 6). For this species, resistance against
erythromycin increased from 36.0% in 2005 to 75.0% in
2014 (P < 0.09) while susceptibility to ciprofloxacin re-
duced (χ2 = 37.2, P < 0.001). S. aureus remained consist-
ently susceptible to vancomycin for the last five years of
the study and during the same time period they showed
an overall 42.0% resistance against ceftriaxone. E. faecalis
was found consistently susceptible to vancomycin between
2010 and 2014, while this species showed an overall 31.0,
45.0, 60.0, 39.0 and 81.0% resistance against ampicillin,
gentamicin (120), ciprofloxacin, penicillin G and co-
trimoxazole respectively (Additional file 8: Table S6).
Discussion
In this retrospective study, we aimed to identify the most
prevalent pathogenic organisms involved in bloodstream
infections (BSI) over a ten year period (2005–14) in pa-
tients in Dhaka, Bangladesh. We also aimed to deter-
mine the antimicrobial susceptibility of the isolated
pathogens against multiple antibiotics to achieve a clear
outlook on the changing trend of their antibiotic
susceptibility.
S. Typhi, the causative agent of typhoid fever, is a major
public health concern in Bangladesh and other developing
Asian countries. Several studies from Bangladesh have
already identified S. Typhi as a common cause of
bloodstream infection in this region [23–25]. We found
Salmonella species to be responsible for almost half of the
disease burden associated with BSI in Dhaka, Bangladesh
and about 80% of these infections were due to S. Typhi.
However, we have observed an overall decrease in
Salmonella species isolation rate over this study period.
This decrease may be attributed to the improved urban
water management system and sanitation practices in
Dhaka city over the past years.
A significant change in the epidemiology of S. Typhi
was observed in early 1990’s as those years experienced
a dramatic rise of MDR strains in Dhaka, Bangladesh
[26]. By mid-1990s, about half of the S. Typhi strains
were MDR; these were resistant against three first line
antibiotics - ampicillin, cotrimoxazole and chloram-
phenicol [26]. Noticeably, after a few years of an initial
epidemic period, a decreasing trend in the isolation rate
of MDR S. Typhi strains was observed [23]. Our study
confirms this trend to continue; from 2005 to 2010, the
percentage of MDR S. Typhi strains isolated declined
from 61.7 to 23.7% (Fig. 2). As indicated by recent studies
from Bangladesh, S. Typhi still shows a high level of resist-
ance against first line antibiotics [23]. However, we have
observed a steady decrease in resistance against ampicillin
and cotrimoxazole over the ten year study period. Hope-
fully, if this trend continues, then using the cheaper, first
line antibiotics again to treat S. Typhi infections might be
a possibility in near future. Ciprofloxacin or ceftriaxone is
Table 3 Percentage of antimicrobial resistance in Salmonella Typhi and Salmonella Paratyphi A, B strains isolated from blood cultures
Salmonella Typhi Salmonella Paratyphi A, B
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
(457)a (595) (571) (600) (483) (643) (451) (527) (354) (509) (85)a (133) (127) (146) (102) (179) (135) (129) (107) (110)
AMP 61 62 54 50 41 41 42 24 28 26 AMP 1 1 0 1 0 0 1 0 1 0
SXT 61 63 54 44 39 34 29 21 24 24 SXT 1 0 0 0 0 0 0 0 1 2
CipR 3 4 2 1 0 2 2 1 1 4 CipR 1 0 0 0 0 0 0 0 0 1
CipI 87 89 88 93 94 94 92 96 92 94 CipI 91 93 97 99 100 99 98 100 98 99
CRO 0 0 0 0 0 0 0 0 0 0 CRO 0 0 0 0 0 0 0 0 0 0
CFM 0 0 0 0 0 0 0 0 1 0 CFM 0 0 1 0 0 0 1 0 0 0
AMP ampicillin, SXT cotrimoxazole, Cip ciprofloxacin, CRO ceftriaxone, CFM cefixime, aValues in parentheses indicate the number of isolates tested each year
Table 4 Percentage of antimicrobial resistance in E. coli strains isolated from blood cultures
E. coli
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2010 2011 2012 2013 2014
(35)a (29) (34) (46) (51) (64) (48) (45) (39) (36) (64) (48) (45) (39) (36)
Amp 88 96 71 79 97 96 93 94 92 92 Net 8 7 7 8 14
SXT 74 75 76 61 73 70 68 73 56 67 Ak 7 4 4 8 14
CN 15 28 24 33 37 36 38 30 44 36 Imp 3 2 4 8 11
CipR 51 48 41 54 63 73 49 71 72 72 Caz 35 30 38 36 56
CipI 0 0 6 2 6 2 2 4 0 0 CFM 69 70 79 68 78
CRO 34 55 32 46 55 63 66 76 69 75
AMP ampicillin, SXT cotrimoxazole, CN gentamicin, Cip ciprofloxacin, CRO ceftriaxone, Net netilmicin, Ak amikacin, Imp imipenem, Caz ceftazidime, CFM cefixime,
aValues in parentheses indicate the number of isolates tested each year
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usually the choice of treatment against MDR Salmonella
strains [27]. We found all Salmonella isolates were con-
sistently susceptible to ceftriaxone, but a very high level of
reduced susceptibility exists against ciprofloxacin. Studies
suggest that the presence of a mutation in the quinolone
resistance-determining region (QRDR) of the gyrA gene is
responsible for the emergence of this reduced suscep-
tibility [28].
Non-fermenter Gram-negative bacilli are well known
for their ability to cause nosocomial infections [29, 30].
We identified Pseudomonas species and Acinetobacter
species to be the third (12.6%) and fifth (5.2%) most
prevalent organisms associated with BSI in Dhaka,
Bangladesh. A gradual decrease in the presence of
Acinetobacter species and a significant increase in the
presence of Pseudomonas species were observed over the
study period. This increase in BSI from Pseudomonas spe-
cies was possibly from the patients increased access to the
health care facilities over these years. Also noticeably,
Pseudomonas species was found to be more associated
with patients above five years of age; almost 70% of the
infections occurring among adults (≥18 years of age). A
recent study from Bangladesh also suggested that there is
a very low amount of bacteremia cases due to Pseudo-
monas species among diarrheal children less than five
years of age [31].
Acinetobacter species and Pseudomonas species are
well known for their high degree of resistance against all
classes of antibiotics, and the emergence of MDR strains
makes it very difficult to treat them. An aminoglycosides
combined with a β-lactamase-stable β-lactam is the typ-
ical choice of treatment for Acinetobacter species infec-
tion [32], and carbapenems are known to be most
effective against their MDR strains [33]. We observed
Acinetobacter species to develop increasingly high levels
of antibiotic resistance against all aminoglycosides, and
noticeably, very high levels of resistance against imipe-
nem (64%). Usually, in the case of resistance against
carbapenems, the expert’s choice of treatment for Acine-
tobacter species infections entails colistin and tigecycline
[34]. We found only 3.73% of the MDR Acinetobacter spe-
cies strains to be resistant against polymyxin B (300 u),
therefore it might be considered as a good treatment
choice against MDR Acinetobacter species. Colistin and
polymyxin B (300 u) are usually considered as the last re-
sort for treatment of infections due to MDR Pseudomonas
species [35], but we observed high levels of resistance
against them. In contrast, we found imipenem to be con-
sistently effective against all Pseudomonas species so it
might be considered as a good choice of treatment.
Besides non-fermenter and Salmonella species, other
clinically important Gram-negative bacteria were E. coli,
Enterobacter species, Klebsiella species and Serratia
species. E. coli has been reported as the leading cause of
BSI in developed countries [1]; however, data is relatively
unavailable for Bangladesh. We found E. coli to be re-
sponsible for only 3.05% of the total BSI cases. It is likely
that the presence of E. coli is overshadowed by the over-
whelming presence of Salmonella species in Dhaka,
Bangladesh, so it would be unwise to ignore them as
clinically insignificant.
A recent study from Bangladesh has shown a very high
level of antibiotic resistance and MDR level among E.
coli isolates from environmental samples [36]. In this
study we identified a much higher level of antibiotic re-
sistance and MDR level (36% MDR in environment sam-
ples vs. 62.38% MDR in our clinical samples) among BSI
causing E. coli strains. We found carbapenems to be the
Table 6 Percentage of antimicrobial resistance in Staphylococcus
aureus strains isolated from blood cultures
Staphylococcus aureus
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
(14)a (10) (15) (23) (26) (30) (25) (23) (23) (30)
Amp 100 100 88 90 88 67 100 100 100 71
SXT 29 20 20 52 35 33 36 23 17 38
C 7 0 7 4 4 4 0 13 4 17
E 36 20 33 78 81 67 72 73 64 75
CipR 25 20 40 65 54 57 64 48 39 67
CipI 8 0 0 0 4 3 4 9 13 0
CN 25 11 20 26 27 33 24 13 22 27
CRO - - - - - 43 29 50 41 45
Van - - - - - 4 0 0 0 0
AMP ampicillin, SXT cotrimoxazole, C chloramphenicol, E erythromycin, Cip
ciprofloxacin, CN gentamicin, CRO ceftriaxone, Van vancomycin, aValues in
parentheses indicate the number of isolates tested each year; − indicates
absence of data in respective years
Table 5 Percentage of antimicrobial resistance in Streptococcus
pneumoniae strains isolated from blood cultures
Streptococcus pneumoniae
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
(49)a (32) (23) (23) (25) (25) (29) (23) (21) (26)
Amp 2 0 0 0 0 0 0 0 0 0
SXT 91 90 87 73 76 91 78 70 71 73
CipR 6 0 5 0 4 0 8 0 0 0
CipI 22 38 24 5 16 0 8 0 9 9
CRO 0 0 0 0 0 0 0 0 0 0
Pen G 2 0 0 0 9 8 3 4 5 8
E 4 0 0 0 8 5 24 23 48 31
Azi - - - - - 7 39 14 55 31
CFM - - - - - 17 0 7 0 8
AMP ampicillin, SXT cotrimoxazole, Cip ciprofloxacin, CRO ceftriaxone, Pen G
penicillin G, E erythromycin, Azi azithromycin, CFM cefixime. aValues in
parentheses indicate the number of isolates tested each year; − indicates
absence of data in respective years
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most active antibiotics against E. coli. Overall, 3.2%
(including MDR strains) of the E. coli strains showed re-
sistance against them. So, carbapenems may be considered
as a good choice of treatment for BSI caused by E. coli.
Klebsiella species showed the highest level of resistance
against β-lactams, especially penicillins and third gener-
ation cephalosporins. Previous studies suggested that car-
bapenems were highly effective against Klebsiella species
until the early years of 2000s. According to Centers for
Disease Control and Prevention (CDC) in the USA,
Klebsiella species acquired the highest amount of carba-
penem resistance (from 1.6 to 10.4%) in the decade from
2001–2011. In accordance with this finding, we observed
a very dramatic rise in Klebsiella species resistance against
imipenem (0 to 46%) and meropenem (0 to 46.5%) from
2005 to 2014. In fact, we found Klebsiella species to show
the highest level of MDR (68%) among all the isolated
pathogens. Overall, E. coli, Klebsiella species and Entero-
bacter species had relatively low prevalence throughout
this study period. However, they should be considered im-
portant as they had the highest amount of MDR strains
and thus the potential to cause serious health threats.
Gram-positive bacteria also pose serious threats as
their incidence in BSI is increasing steadily worldwide.
The problem is particularly acute in nosocomial settings
where methicillin-resistant S. aureus (MRSA) and vanco-
mycin resistant Enterococcus (VRE) are considered ser-
ious health threats [37, 38]. In this study, we observed
an increasing trend in the isolation rate of Gram-
positive bacteria. This trend may be attributed to the pa-
tient’s increased access to the health care facilities where
BSI from Gram-positive bacteria is common. We identi-
fied S. aureus and S. pneumoniae as the two major
Gram-positive pathogenic bacteria associated with BSI
in Dhaka, Bangladesh. S. pneumoniae reportedly kills
about 0.7 to 1 million children under five years of age
every year worldwide and 90% of these deaths occur in
developing countries [39]. Pneumonia is the primary
cause of childhood death in Bangladesh [40] and studies
suggest that the incidence of pneumonia among pre-
school children in Bangladesh is surprisingly higher than
in developed countries [41, 42]. We found almost 75% of
the BSI cases from S. pneumoniae to occur among chil-
dren less than five years of age. However, a decreasing
trend in their isolation rate was observed throughout
this study period.
Increasing levels of antibiotic resistance are a big con-
cern for S. pneumoniae, especially their resistance
against macrolides and β-lactams, which are the first
choice of treatment for most pneumonia cases. One re-
cent review indicates a very high level of penicillin resist-
ance among S. pneumoniae strains in different Asian
countries [43]. However, we observed only a small in-
crease in penicillin resistance in Dhaka, Bangladesh.
Another study from Dhaka indicates the presence of
high level of resistance against ciprofloxacin. However
our study found a much lower level of resistance against
ciprofloxacin and also we observed a decreasing trend in
their susceptibility pattern [44]. Ampicillin and ceftriax-
one were found to be consistently active against S. pneu-
moniae, so they might be considered as good treatment
choices for them. Emergence of MRSA strain marks an-
other very important epidemiological change for the past
few decades [45]. Naturally, S. aureus are susceptible to
commonly used antibiotics. However methicillin resist-
ance is associated with resistance against a broad range
of antibiotics [46]. Over the study period, we found over-
all 50.2% of S. aureus strains to be MDR. In the first five
years of our study, we identified 34.4% of the S. aureus
strains to be oxacillin (a synthetic form of methicillin)
resistant; however, the percentage was much higher
(58.7%) amongst the MDR strains. Vancomycin has been
Fig. 2 Decrease of multidrug-resistant (MDR) Salmonella Typhi isolation rate from blood cultures
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widely used as the preferred choice of treatment for
MRSA strains [47], and we also found vancomycin to be
highly effective against all S. aureus strains; only 2.1%
strains were resistant. Linezolid was also found to be
very effective against S. aureus; only one resistant strain
was detected over the study period. Therefore, both
vancomycin and linezolid might be considered as a good
treatment choices against S. aureus which are resistant
to commonly used antibiotics.
Limitations of the study
Due to the lack of resources, we were not able to differ-
entiate the samples received from our hospital patients
and from domiciliary patients. As a result we could not
show the difference in epidemiology between nosoco-
mial and community acquired BSI. Also due to lack of
resources, we were not able to collect patient data on
the clinical manifestations or any other patient charac-
teristics, other than age and sex, which could be consid-
ered as risk factors for BSI. However, we confirm that
each patient was diagnosed with signs of bacteremia by
their respective physicians. Also, we were not able to
perform any molecular tests on received samples due to
lack of required resources.
Conclusion
This study clearly identifies the bacterial pathogens in-
volved with bloodstream infections (BSI) occurring in
Dhaka, Bangladesh between January 2005 to December
2014. It also reveals their antibiotic susceptibility patterns
for commonly used antibiotics. We expect our findings to
help healthcare professionals to make informed decisions
and provide better care for their patients. Also, we hope
this study to help researchers and policy makers to
prioritize their research options to face future challenges
of infectious diseases both at home and abroad.
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